Editorial: Decoding checkpoint inhibitor-induced endocrinopathies

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies

Bibliographic Details
Main Authors:	Deborah L. Burnett, Megan B. Barnet, Katherine Samaras
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Endocrinology
Subjects:	immune checkpoint (ICP) cancer immunotherapies irAE autoimmune disease endocrinopathies
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2022.987648/full

Similar Items

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
by: Adrian Chye, et al.
Published: (2022-07-01)

Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II
by: Deborah L. Burnett, et al.
Published: (2023-10-01)

Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival
by: Lisa Yang, et al.
Published: (2024-04-01)

Immune Checkpoint Inhibitors and Lupus Erythematosus
by: Hans Vitzthum von Eckstaedt, et al.
Published: (2024-02-01)

Molecular analysis of immune checkpoint inhibitor associated erythema nodosum-like toxicity
by: Xiaopeng Sun, et al.
Published: (2025-03-01)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
by: Vanita Noronha, et al.
Published: (2021-03-01)

Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer
by: Ruth Percik, et al.
Published: (2023-04-01)

Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports
by: Meng H. Tan, et al.
Published: (2019-01-01)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
by: Raju Vaddepally, et al.
Published: (2022-03-01)

HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment
by: Sophia Gandarillas, et al.
Published: (2024-01-01)

Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis
by: Naoki Hamada, et al.
Published: (2021-12-01)

Fever of unknown origin associated with immune checkpoint inhibitors
by: Xu Tong, et al.
Published: (2024-03-01)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
by: A.B. Pierre, et al.
Published: (2023-12-01)

Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial
by: Lærke K. Tolstrup, et al.
Published: (2022-01-01)

Immune Checkpoint Inhibitors‐Induced Endocrinopathies: Assessment, Management and Monitoring in a Comprehensive Cancer Centre
by: Omayma Elshafie, et al.
Published: (2024-07-01)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
by: Ji Li, et al.
Published: (2022-05-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
by: Alicia Quilez, MD, et al.
Published: (2020-03-01)

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
by: Betul Ibis, et al.
Published: (2023-06-01)

A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy
by: Yuki Haruta, et al.
Published: (2024-02-01)

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
by: D. I. Yudin, et al.
Published: (2020-07-01)

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
by: Ana Cardeña-Gutiérrez, et al.
Published: (2022-06-01)

Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?
by: Teresa Squicciarini, et al.
Published: (2024-05-01)

Immune Checkpoint Inhibitor-Associated Myocarditis
by: Grigorios Chatzantonis, MD, et al.
Published: (2020-04-01)

Correlation between thyroid dysfunction and efficacy of immune checkpoint inhibitors in patients with advanced solid tumors
by: Cheng Zhao
Published: (2024-11-01)

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
by: John A. Storwick, et al.
Published: (2024-04-01)

A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
by: Philip Friedlander, et al.
Published: (2018-09-01)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-02-01)

Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis
by: Andrés Ponce, et al.
Published: (2022-08-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
by: Jing Xiang, et al.
Published: (2023-12-01)

Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
by: Yutaka Takahara, et al.
Published: (2023-09-01)

Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis
by: Agnese Paderi, et al.
Published: (2021-09-01)

Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series
by: Sarah Picard, et al.
Published: (2021-07-01)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
by: Peng Song, et al.
Published: (2020-09-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
by: T. Anders Olsen, et al.
Published: (2022-03-01)

Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
by: Carmen Portenkirchner, et al.
Published: (2021-04-01)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
by: Scott S. Tykodi, et al.
Published: (2023-04-01)

Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
by: Sae Ohwada, et al.
Published: (2022-06-01)

Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody
by: Shin Urai, et al.
Published: (2023-11-01)